"Cyclopropanes" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Three-carbon cycloparaffin cyclopropane (the structural formula (CH2)3) and its derivatives.
| Descriptor ID |
D003521
|
| MeSH Number(s) |
D02.455.426.392.368.533
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Cyclopropanes".
Below are MeSH descriptors whose meaning is more specific than "Cyclopropanes".
This graph shows the total number of publications written about "Cyclopropanes" by people in this website by year, and whether "Cyclopropanes" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 1 | 0 | 1 |
| 2003 | 1 | 0 | 1 |
| 2005 | 0 | 1 | 1 |
| 2006 | 2 | 0 | 2 |
| 2007 | 0 | 3 | 3 |
| 2008 | 0 | 2 | 2 |
| 2009 | 1 | 4 | 5 |
| 2010 | 1 | 0 | 1 |
| 2011 | 0 | 2 | 2 |
| 2012 | 2 | 5 | 7 |
| 2013 | 0 | 4 | 4 |
| 2014 | 1 | 7 | 8 |
| 2015 | 1 | 2 | 3 |
| 2016 | 0 | 4 | 4 |
| 2017 | 1 | 6 | 7 |
| 2018 | 1 | 4 | 5 |
| 2019 | 0 | 1 | 1 |
| 2020 | 4 | 1 | 5 |
| 2021 | 0 | 3 | 3 |
| 2022 | 0 | 1 | 1 |
| 2024 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cyclopropanes" by people in Profiles.
-
Impact of efavirenz on hormone-positive breast cancer survival in women living with HIV. AIDS. 2024 07 15; 38(9):1439-1442.
-
Montelukast as a repurposable additive drug for standard-efficacy multiple sclerosis treatment: Emulating clinical trials with retrospective administrative health claims data. Mult Scler. 2024 May; 30(6):696-706.
-
Treatment of hepatitis C virus infection in people with opioid use disorder: a real-world study of elbasvir/grazoprevir in a US Department of Veterans Affairs population. Am J Drug Alcohol Abuse. 2022 07 04; 48(4):445-453.
-
Phase I trials of the lysine-specific demethylase 1 inhibitor, GSK2879552, as?mono- and combination-therapy in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes. Leuk Lymphoma. 2022 02; 63(2):463-467.
-
A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE Study. Hepatology. 2021 12; 74(6):2952-2964.
-
Tasimelteon safely and effectively improves sleep in Smith-Magenis syndrome: a double-blind randomized trial followed by an open-label extension. Genet Med. 2021 12; 23(12):2426-2432.
-
Infection or drug toxicity? Acute ataxia and encephalopathy after uncomplicated falciparum malaria and efavirenz dose adjustment. Malawi Med J. 2020 12; 32(4):229-231.
-
Leukotrienes, a potential target for Covid-19. Prostaglandins Leukot Essent Fatty Acids. 2020 10; 161:102174.
-
Safety and tolerability of elbasvir/grazoprevir in chronic hepatitis C virus therapy: Integrated analysis from clinical trials. J Viral Hepat. 2020 11; 27(11):1222-1233.
-
The Pharmacogenetics of Efavirenz Metabolism in Children: The Potential Genetic and Medical Contributions to Child Development in the Context of Long-Term ARV Treatment. New Dir Child Adolesc Dev. 2020 May; 2020(171):107-133.